Peptide-based vaccination for colorectal cancer

Bibliography

• ARBER N, LEVIN B: Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res. (2005) 166:213–230.
   Google Scholar
• ZANIBONI A, LABIANCA R: Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Oncol (2004) 15:1310–1318.
   Google Scholar
• COUTINHO AK, ROCHA LIMA CM: Metastatic colorectal cancer systemic treatment in the new millennium. Cancer Control (2003) 10:224–238.
   PubMedGoogle Scholar
• FOON KA, YANNELLI J, BHATTACHARYA-CHATTERJEE M: Colorectal cancer as a model for immunotherapy. Clin. Cancer Res. (1999) 5:225–236.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol (2000) 18:767–811.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• ALLISON JP, HURWITZ AA, LEACH DR: Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol (1995) 7:682–686.
   PubMed Web of Science ®Google Scholar
• GRETEN TF, JAFFEE EM: Cancer vaccines. J. Clin. Oncol. (1999) 17:1047–1060.
   PubMed Web of Science ®Google Scholar
• ROCK KL, GAMBLE S, ROTHSTEIN L:Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (1990) 249:918–921.
   PubMed Web of Science ®Google Scholar
• GRANT EP, ROCK KL: MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol (1992) 148:13–18.
   PubMed Web of Science ®Google Scholar
• ROCK KL, ROTHSTEIN L, GAMBLES, FLEISCHACKER C: Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol (1993) 150:438–446.
   PubMed Web of Science ®Google Scholar
• HARDING CV, SONG R: Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol (1994) 153:4925–4933.
   PubMed Web of Science ®Google Scholar
• KOVACSOVIC-BANKOWSKI M, ROCK KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 267:243–245.
   PubMed Web of Science ®Google Scholar
• TAMURA Y, KUROTAKI T, IMAI A, TORIGOE T, SATO N: Exogenous HSP90-peptide complexes-loaded dendritic cells elicit crosspresentation to cytotoxic T lymphocytes: application for cancer vaccine. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5–7 November 2004).
   Google Scholar
• SWAIN SL, BRADLEY LM, CROFT M et al.: Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol. Rev. (1991) 123:115–144.
   PubMed Web of Science ®Google Scholar
• MACKAY CR: Immunological memory. Adv. Immunol (1993) 53:217–265.
   PubMed Web of Science ®Google Scholar
• JAGER E, RINGHOFFER M, DIENES HP et al.: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer (1996) 67:54–62.
   PubMed Web of Science ®Google Scholar
• MURRAY JL, GILLOGLY ME, PRZEPIORKA D et al.: Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2 patients with metastatic breast and ovarian cancer. Clin. Cancer Res. (2002) 8:3407–3418.
   PubMed Web of Science ®Google Scholar
• TORIGOE T, TSURUMA T, SHIJYUBOU Net al.: Phase I clinical study assessing survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal, breast or lung cancer. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5–7 November 2004).
   Google Scholar
• TSURUMA T, HATA F, TORIGOE T et al.: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl Med. (2004) 2:19–29.
   PubMedGoogle Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• KUROTAKI T, TAMURA Y, HIRATA K, SATO N: Effective induction of CTLs by immunization with HSP90-cancer peptide complex. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5–7 November 2004).
   Google Scholar
• ••Investigation of immunisation withhsp90-cancer peptide complex, which induced the cytotoxicity of CTLs.
   Google Scholar
• MAZZAFERRO V, COPPA J, CARRABBA MG et al.: Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. (2003) 9:3235–3245.
   PubMed Web of Science ®Google Scholar
• ••A clinical trial that was carried out usingautologous tumour-derived HSPPC-96 to vaccinate patients after resection of liver metastases of colorectal carcinoma.
   Google Scholar
• SHANG XY, CHEN HS, ZHANG HG et al.: The spontaneous CD8 T-cell response to HLA-A2-restricted NY-ESO-lb peptide in hepatocellular carcinoma patients. Clin. Cancer Res. (2004) 10:6945–6955.
   Web of Science ®Google Scholar
• HOBEIKA AC, MORSE MA, OSADA T et al.: Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. Immunother. (2005) 28:63–72.
   PubMed Web of Science ®Google Scholar
• ••Investigation of antigen-specific T cellresponses: peptide/MHC tetramer analysis, ELISPOT assay and intracellular cytokine flow cytometry analysis.
   Google Scholar
• -WHITESIDE TL, ZHAO Y, TSUKISHIRO T, ELDER EM, GOODING W, BAAR J: Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. (2003) 9:641–649.
   PubMed Web of Science ®Google Scholar
• ••Investigation of antigen-specific T cellresponses: peptide/MHC tetramer analysis, ELISPOT assay and intracellular cytokine flow cytometry analysis.
   Google Scholar
• MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer (1999) 80:219–230.
   PubMed Web of Science ®Google Scholar
• CLEMENTE CG, MIHM MC JR, BUFALINO R, ZURRIDA S, COLLINI P, CASCINELLI N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 77:1303–1310.
   PubMed Web of Science ®Google Scholar
• DUNBAR PR, SMITH CL, CHAO D et al.: A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. (2000) 165:6644–6652.
   PubMed Web of Science ®Google Scholar
• ROMERO P, DUNBAR PR, VALMORI D et al.: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. (1998) 188:1641–1650.
   PubMed Web of Science ®Google Scholar
• SMITH CL, DULPHY N, SALIO M, CERUNDOLO V: Immunotherapy of colorectal cancer. Br. Med. Bull. (2002) 64:181–200.
   PubMed Web of Science ®Google Scholar
• GOYDOS JS, ELDER E, WHITESIDE TL, FINN OJ, LOTZE MT: A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. Surg Res. (1996) 63:298–304.
   Google Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• GONZALEZ G, CROMBET T, CATALA M et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann. Oncol (1998) 9:431–435.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• SATO Y, MAEDA Y, SHOMURA H et al: A Phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer (2004) 90:1334–1342.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• TSUDA N, MOCHIZUKI K, HARADA M et al.: Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J. Immunother. (2004) 27:60–72.
   PubMed Web of Science ®Google Scholar
• MOULTON HM, YOSHIHARA PH, MASON DH, IVERSEN PL, TRIOZZI PL: Active specific immunotherapy with a O-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. (2002) 8:2044–2051.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• MIYAGI Y, IMAI N, SASATOMI T et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. (2001) 7:3950–3962.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
   Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321–327.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer (1999) 80:219–230.
   PubMed Web of Science ®Google Scholar
• WANG F, BADE E, KUNIYOSHI C et al: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. (1999) 5:2756–2765.
   PubMed Web of Science ®Google Scholar
• JAGER E, NAGATA Y, GNJATIC S et al: Monitoring CD8 T cell responses to NY-ES0-1: correlation of humoral and cellular immune responses. Proc. Nail. Acad. Sci. USA (2000) 97:4760–4765.
   PubMed Web of Science ®Google Scholar
• HIROHASHI Y, TORIGOE T, MAEDA A et al.: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. (2002) 8:1731–1739.
   PubMed Web of Science ®Google Scholar
• IDENOUE S, HIROHASHI Y, TORIGOE T et al.: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. (2005) 15:1474–1482.
   Web of Science ®Google Scholar
• MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10:1278–1279.
   PubMed Web of Science ®Google Scholar
• VALMORI D, DUTOIT V AYYOUB M et al.: Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. (2003) 3:15.
   Google Scholar
• LETSCH A, KEILHOLZ U, FLUCK M et al.: Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Int. J. Cancer (2005) 114(6):936–941.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial of adjuvant peptide vaccinetherapy that induced a prolonged relapse-free interval.
   Google Scholar
• VERMORKEN JB, CLAESSEN AM, VAN TINTEREN H et al.: Active specific immunotherapy for stage II and stage III human colon cancer. A randomized trial. Lancet (1999) 30:345–350.
   Google Scholar
• ••Clinical trial of adjuvant immunotherapyin surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
   Google Scholar
• HOOVER HC, BRANDHORST JS, PETERS LC et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. Clin. Oncol (1993) 11:390-399. ••Clinical trial of adjuvant immunotherapyin surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
   Google Scholar
• HARRIS JE, RYAN L, HOOVER HC et al: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern cooperative oncology group study E5283. J. Clin. Oncol (2000) 18:148–157.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial of adjuvant immunotherapyin surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
   Google Scholar
• MITCHELL MS: Immunotherapy as partof combinations for the treatment of cancer. Int. Immunopharmacol (2003) 3:1051–1059.
   PubMed Web of Science ®Google Scholar